Astec Lifesciences Ltd

Astec Lifesciences Results Update

Astec LifeSciences released a press release on its Q2 and H1 FY27 results, approved October 26, 2026. Q2 FY27 losses widened year on year.

Astec Lifesciences Other Announcement

Astec LifeSciences filed a Reg 54 Nil Security Cover certificate for its listed unsecured NCDs, stating the security cover format is not applicable. This is routine compliance paperwork with no new money or business event.

Astec Lifesciences Q2 FY27 Results: Net Loss of ₹37.4 Cr, Loss Widens

Astec Lifesciences Ltd reported revenue from operations of ₹72 Cr (-2.3% YoY) and a net loss of ₹37.4 Cr for Q2 FY27.

Key figure

Net loss ₹37.4 Cr

Astec Lifesciences Board Meeting Date

Astec LifeSciences will hold a board meeting on October 26, 2026, to consider and approve standalone and consolidated unaudited financial results for the half-year ending September 2026.

Astec Lifesciences Other Announcement

Astec Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited has redeemed Commercial Papers amounting to ₹25 Crore. The payment was made on the maturity date, 13th October, 2026.

Value

₹25.00 Cr

Astec Lifesciences Other Announcement

Astec Lifesciences filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026, confirming no rematerialization requests received.

Astec Lifesciences Debt & Borrowing: ₹75 Cr

Astec LifeSciences fixed record dates for redemption of three CP series totaling Rs.75 Crore maturing Nov–Dec 2026. All three CPs are listed on the NSE debt segment.

Value

₹75.00 Cr

Astec Lifesciences Price Movement Clarification

Astec LifeSciences Limited clarified there are no undisclosed material developments explaining the recent significant increase in share trading volume. The company confirmed full compliance with SEBI listing regulations.

Astec Lifesciences Price Movement Clarification

Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.

Value

₹25.00 Cr

Astec Lifesciences Price Movement Clarification

Astec LifeSciences replied to an NSE volume-spike surveillance notice, confirming full disclosure compliance. No undisclosed developments exist under Listing or PIT Regulations.

Astec Lifesciences Debt & Borrowing: ₹75 Cr

Astec LifeSciences has set record dates for the redemption of three Commercial Paper series, with each series maturing at a value of ₹25 Crore.

Value

₹75.00 Cr

Astec Lifesciences Annual General Meeting

Astec LifeSciences held its 32nd AGM on July 31, 2026. The meeting approved financial statements, director re-appointment, and cost auditor remuneration.

Astec Lifesciences Results Update

Astec LifeSciences announced its Q1 FY27 financial results, reporting total income of ₹84.3 crore and an EBITDA of ₹0.1 crore.

Astec Lifesciences Other Announcement

Astec LifeSciences confirmed nil deviation in the utilization of proceeds from its listed Non-Convertible Debentures for the quarter ended 30th June, 2026.

Astec Lifesciences Q1 FY27 Results: Net Loss of ₹18.7 Cr, Loss Narrows

Astec Lifesciences Ltd reported revenue from operations of ₹83.6 Cr (-8.2% YoY) and a net loss of ₹18.7 Cr for Q1 FY27.

Key figure

Net loss ₹18.7 Cr

Astec Lifesciences Board Meeting Date

Astec LifeSciences Ltd scheduled a board meeting on July 31, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.

Astec Lifesciences Other Announcement

Astec Lifesciences Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing lists promoters and public shareholders' stakes.

Astec Lifesciences Annual General Meeting

Astec LifeSciences scheduled its AGM for July 31, 2026. Agenda includes financial statement adoption, director re-appointment, and ratifying auditor remuneration of Rs. 0.015 Crore.

Value

₹0.01 Cr

Astec Lifesciences Annual Report

Astec LifeSciences submitted its FY 2025-26 Annual Report and AGM notice. The 32nd Annual General Meeting is scheduled for July 31, 2026.

Astec Lifesciences Management Change

Astec LifeSciences appointed five directors, including Vishal Sharma as Chairperson. Other appointees include Burjis N. Godrej and Arijit Mukherjee to strengthen leadership.

Astec Lifesciences Annual General Meeting

Astec Lifesciences Ltd announced the outcome of its Postal Ballot, with all resolutions passed by overwhelming majority. The results, including director appointments, were filed with stock exchanges.

Astec Lifesciences Management Change

Ms. Vijayalakshmi Iyer has resigned as General Manager – Human Resources at Astec LifeSciences Limited. This senior management departure is for pursuing new career opportunities.

Astec Lifesciences Annual General Meeting

Astec LifeSciences issued a postal ballot notice for director appointments and related party transactions. Proposed transaction limits with Godrej group entities total ₹405 Crore for FY2026-27.

Value

₹405.0 Cr

Execution

FY 2026-27

Astec Lifesciences Annual General Meeting

Astec LifeSciences issued a postal ballot notice for director appointments and related party transactions. Shareholders can vote electronically from June 5 to July 4, 2026.

Astec Lifesciences Employee Stock Options

Astec LifeSciences Limited allotted 582 equity shares following the exercise of stock options under its ESOP scheme. The issuance marginally increases the company's total paid-up share capital.

Astec Lifesciences Employee Stock Options

Astec LifeSciences Limited allotted 582 equity shares under its ESOP scheme. This marginal capital increase reflects the ongoing exercise of employee stock options.

Value

₹0.01 Cr

Astec Lifesciences Employee Stock Options

Astec LifeSciences Limited allotted 582 equity shares following the exercise of employee stock options. The company realized Rs.5,820 from this allotment at an exercise price of Rs.10.

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited successfully redeemed its listed Commercial Paper worth ₹25 Crore on maturity. The timely payment reinforces the company's financial discipline and debt servicing reliability.

Value

₹25.00 Cr